Study of Ravulizumab in Pediatric Participants With Primary IgAN
Study Identifier:
D928FC00002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Will Be Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Sep 2025 - Oct 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 18 Years
Requirements Information
Sex
Female & Male
Age
2 - 18 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Sep 2025 - Oct 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 18 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with ravulizumab IV in pediatric participants to support the extrapolation of efficacy from the adult population.
Trial Locations
Location
Status
Location
Research Site
Aurora, Colorado, United States, 80045
Status
N/A
Location
Research Site
Beijing, China, 100045
Status
N/A
Location
Research Site
Shanghai, China, 201102
Status
N/A
Location
Research Site
Genova, Italy, 16147
Status
N/A
Location
Research Site
Roma, Italy, 00165
Status
N/A
Location
Research Site
Torino, Italy, 10126
Status
N/A